Users of TAF in PrEP more likely to develop high blood pressure or need statins
“A study of people who started PrEP in a southern California health system has found that people who took PrEP containing tenofovir alafenamide (TAF) were more likely to be diagnosed with high blood pressure or start treatment with a statin to control cholesterol than those taking PrEP containing tenofovir disoproxil (TDF) during a two-year follow-up.”… Read More »